August 25th 2025
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
August 19th 2025
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
August 15th 2025
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
August 14th 2025
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
August 13th 2025
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion
Don’t miss our editorial advisory board members at the Floretina/ICOOR meeting
EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of care
Breakthrough technologies are raising the ceiling for functional visual outcomes
The Floretina ICOOR meeting begins in Florence, Italy
What to expect from 4 days in the Fortezza de Basso
EMA grants orphan medicinal product designation for OCU410ST (Ocugen)
OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases
CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)
The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union
US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)
The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration
NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
How a gene-agnostic approach opens doors to new therapeutics
Arun Upadhyay, PhD, discusses new study findings from trials of OCU400 (Ocugen)
US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy
HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration
Zooming in on geographic atrophy with OCT-based AI
New analysis brings disease progression and therapeutics into focus
Excellence across the board at the 2024 EURETINA congress
This year’s Barcelona meeting brought together award-winning research data and leaders in the retina field
Study: caffeine does not impact retinal vessel density, despite effects on blood pressure
Caffeine has been shown to temporarily increase intraocular pressure and reduce blood flow in critical ocular regions
Ikerian announces commercial expansion of RetinAI Discovery in Europe
New investment from Sanoptis will support Ikerian technology for large-scale, AI-enabled data management
Ocuphire Pharma and Opus Genetics announce merger
The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.
AAO 2024: Late-breaking developments in a novel treatment for adolescents with Stargardt disease
A novel oral therapeutic showed promising results in a Phase 2 study involving 13 subjects
Treatment and technology: The future of retina care
How robotics and gene therapies are shaping retina research, now and in the days to come
Alzheimer disease retinopathy and brain-to-eye β-amyloid transport
The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease
Study: Oral caffeine intake increases inner electro-retinal activity in young adults
Investigators studied global-flash multifocal electroretinogram responses
What's missing in patient education?
A different approach better serves patients with diabetic retinopathy
EURETINA 2024: David Yorston, FRCS, FRCOphth, says data can unify us
Dr Yorston delivered the Gisbert Richard Lecture at this year's EURETINA Congress
EURETINA 2024: CRISPR-Cas mediated base editing approaches for CRB1 related retinal dystrophy
The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress
EURETINA 2024: New therapeutics for wet AMD address the broader VEGF family
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
EURETINA 2024: Carl Awh, MD, FASRS, and the American Society of Retina Specialists collaborate at EURETINA
Carl Awh, MD, FASRS, spoke the value of the international community of retina clinicians connecting at global meetings
EU CHMP confirms negative opinion on marketing authorisation application of intravitreal pegcetacoplan from Apellis
The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response
EURETINA 2024: Genotype-phenotype correlations in a cohort of patients with genetically determined retinitis pigmentosa
Stefano Mercuri, MD, speaks about his team's August Deutman award-winning research on retinitis pigmentosa and Rho gene mutations
EURETINA 2024: The global VOYAGER study provides real-world, scalable findings
Clare Bailey, MD, shared data from the multi-country study on faricimab for patients with DME and nAMD
EURETINA 2024: Bahram Bodaghi, MD, PHD, FEBO, says the Congress "starts with innovation"
Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)